Comparative Analysis of Two Transforaminal Lumbar Interbody Fusion (TLIF) Procedures in the Treatment of Single-Level Lumbar Spinal Stenosis (LSS): A Single-Center, Prospective, Randomized Controlled Trial
Comparative Analysis of L-Unitary Soft Endoscope Transforaminal Lumbar Interbody Fusion (LUSE-TLIF) Versus Minimally Invasive Transforaminal Lumbar Interbody Fusion (MIS-TLIF) in the Treatment of Single-Level Lumbar Spinal Stenosis (LSS): A Single-Center, Prospective, Randomized Controlled Trial
調査の概要
詳細な説明
Lumbar spinal stenosis (LSS) is a common degenerative condition of the lumbar spine. In its narrow definition, LSS primarily refers to central canal stenosis resulting from facet joint hypertrophy and thickening of the ligamentum flavum. Broadly, it also encompasses lateral recess stenosis and bony stenosis within the intervertebral foramen region, categories that some scholars group under lateral canal stenosis. The main symptoms of LSS include low back pain, leg pain, and neurogenic claudication, which impair patients' quality of life and severely limit function, particularly in the elderly. With the aging global population, the prevalence of LSS is rising, affecting approximately 103 million patients worldwide. Treatment options for LSS include both conservative and surgical management. Conservative treatments encompass medication, physical therapy, and lifestyle modifications. However, surgical intervention may be necessary for LSS patients who do not respond adequately to conservative therapies.
Lumbar interbody fusion (LIF) is commonly employed to treat various spinal pathologies, particularly lumbar spinal stenosis. Currently, LIF can be performed via open or minimally invasive approaches, including transforaminal, posterior, anterior, and lateral routes, each with its own advantages and disadvantages. Generally, posterior lumbar interbody fusion (PLIF) is a well-established procedure associated with good fusion rates and relatively low complication rates. However, it carries the risk of iatrogenic injury to neural structures and paraspinal muscles. Despite demonstrating favorable early outcomes, PLIF has notable limitations, including a relatively high complication rate and a challenging recovery process. In 1982, transforaminal lumbar interbody fusion (TLIF) was introduced, which offers a less traumatic and safer unilateral interbody fusion technique. TLIF addresses several shortcomings of PLIF, leading to its rapid adoption and continuous refinement within the spine surgery community. Nevertheless, traditional open TLIF faces challenges such as significant tissue trauma, potential muscle atrophy, chronic postoperative low back pain, and adjacent segment instability.
The advent of various minimally invasive techniques has helped reduce muscle injury and irritation to the posterior spinal elements. To minimize surgical trauma and facilitate rapid recovery, minimally invasive transforaminal lumbar interbody fusion (MIS-TLIF) was developed. A meta-analysis published in 2017 reported that MIS-TLIF could lower postoperative complication rates compared to conventional open procedures. Furthermore, MIS-TLIF demonstrates significant efficacy in protecting muscles (e.g., the multifidus) and ligaments. A comparative study indicated that the rates of postoperative complications and reoperations at 2-year and 3-year follow-ups were significantly lower for MIS-TLIF than for traditional TLIF. However, despite the improved visualization provided by the endoscope in MIS-TLIF, visual blind spots may still exist in certain complex anatomical areas, potentially leading to incomplete assessment of the pathological site and suboptimal placement of internal fixation devices. Additionally, MIS-TLIF relies on traditional open pedicle screw fixation, which may increase the long-term risk of postoperative chronic low back pain.
To address the aforementioned clinical challenges, our research team independently developed a L-Unitary Soft Endoscope minimally invasive system, termed LUSE (Chinese National Invention Patent: CN117017466B). It completed filing as a Class I medical device with the Guangzhou Market Supervision Administration in 2021 (Filing No.: 20210598) and is classified as a set of fundamental orthopedic surgical instruments, with its filing status remaining valid. The system features a highly integrated, all-in-one design that combines key components such as the display, camera, light source, and transmission system into a single unit, simplifying operation and maintenance. During development, particular attention was paid to controlling the size and weight of the endoscope, resulting in a compact and lightweight soft endoscope with a diameter of 1.8 mm and a length of 2-4 cm. Its volume and weight are reduced by approximately 93% compared to traditional endoscopes. This endoscope integrates multiple functions including illumination, imaging, and recording, significantly enhancing procedural convenience and patient comfort.
Compared to the traditional MIS-TLIF performed under a Quadrant expandable retractor system, the highly integrated LUSE system offers several advantages in lumbar minimally invasive fusion surgery: (1) The LUSE system supports 8K ultra-high-definition imaging, providing clear and detailed visualization of the surgical field, whereas the Quadrant retractor system only provides illumination without endoscopic magnification, limiting the ability to visualize fine anatomical structures; (2) LUSE-TLIF utilizes a percutaneous pedicle screw system, minimizing injury to the lumbar back muscles, ligaments, and blood vessels. In contrast, MIS-TLIF requires the placement of pedicle screws via a traditional open approach, which may increase the long-term incidence of chronic back pain; (3) The soft lens of the LUSE system offers 360-degree flexibility, whereas the Quadrant retractor system has inherent visual blind spots that can hinder adequate decompression and optimal implant placement. Therefore, LUSE-TLIF holds multiple advantages over MIS-TLIF. Our team has previously demonstrated the safety and efficacy of the LUSE system in anterior cervical discectomy and fusion (ACDF) and artificial disc replacement (ADR) procedures, with related studies published in leading Chinese journals such as the Chinese Journal of Orthopaedicsand the Chinese Journal of Spine and Spinal Cord. However, there is currently a lack of clinical research in China evaluating the efficacy of LUSE-TLIF for treating LSS. Consequently, this study aims to apply LUSE-TLIF for LSS treatment, observe its safety, efficacy, and clinical outcomes, and conduct a comparative analysis with MIS-TLIF, with the goal of providing spine surgeons with an additional and potentially superior surgical option.
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Kaiting Chen, PhD
- 電話番号:+86 020-62784332
- メール:1190011049@smu.edu.cn
研究場所
-
-
Guangdong
-
Guangzhou、Guangdong、中国、515000
- 募集
- The Third Affiliated Hospital of Southern Medical University
-
コンタクト:
- Kaiting Chen, PhD
- 電話番号:+86 020-62784332
- メール:1190011049@smu.edu.cn
-
-
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- Age ranging from 40 to 70 years, irrespective of sex.
- Presence of bilateral lower-limb pain and neurogenic claudication, with or without low back pain.
- Preoperative computed tomography or magnetic resonance imaging confirming single-level lumbar spinal stenosis accompanied by grade II or higher lumbar spondylolisthesis and/or lumbar instability.
- Persistent pain within 7 days prior to enrollment, with inadequate response to nonsurgical treatment for more than 3 months.
- Willingness to provide written informed consent and ability to comply with the study protocol and visit schedule.
Exclusion Criteria:
- Patients with evidence of vascular claudication identified by lower-limb color Doppler ultrasound.
- Patients with a history of previous lumbar spine surgery.
- Coexistence of severe lumbar disc herniation, spinal deformity, spinal tumor, infection, or inflammatory diseases.
- Pregnancy or lactation.
- Presence of severe underlying medical conditions or psychiatric disorders that preclude tolerance of the procedure.
- Known concurrent diseases considered by the investigator to preclude study entry.
- Inability to comply with study assessments or complete questionnaires for any reason.
- Patients deemed unsuitable for participation in this trial as judged by the investigator.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:トリプル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:LUSE-TLIF
The subject underwent LUSE-TLIF surgery
|
LUSE-TLIF is a TLIF procedure performed through the LUSE system.
他の名前:
|
|
アクティブコンパレータ:MIS-TLIF
Subjects underwent MIS-TLIF surgery assisted by the Quadrant channel
|
MIS-TLIF is a TLIF procedure performed through the Quadrant channel and other systems.
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Vertebral Fushion
時間枠:3-month, 6-month, 1-year, 2-year, 3-year, 5-year post-operation
|
Assess vertebral fusion status through imaging indicators and clinical symptoms.
Vertebral fusion was established as the clinical outcome, defined as: (1) Clinical fusion: a. absence of mechanical low back pain and intermittent claudication; b. dynamic flexion-extension radiographs demonstrating motion angle of the surgical segment less than 4°; (2) Bony fusion: a. Bridwell grade A or B; b. increase in segmental lordosis angle of the surgical segment ≥3° compared to baseline; (3) simultaneous achievement of both clinical and bony fusion.
|
3-month, 6-month, 1-year, 2-year, 3-year, 5-year post-operation
|
|
ODI
時間枠:baseline, 3-day, 3-month, 6-month, 1-year, 2-year, 3-year, 5-year post-operation
|
The ODI score refers to the Oswestry Disability Index, a widely used questionnaire that measures the level of disability in individuals with low back pain.
It consists of ten sections assessing daily activities, with scores ranging from 0 to 100; higher scores indicate more severe disability.
|
baseline, 3-day, 3-month, 6-month, 1-year, 2-year, 3-year, 5-year post-operation
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
VAS
時間枠:baseline, 3-day, 3-month, 6-month, 1-year, 2-year, 3-year, 5-year post-operation
|
The VAS score refers to the Visual Analogue Scale, a tool used to measure leg and back pain intensity.
Patients mark a point on a 10-cm line, where one end represents "no pain" (0) and the other "worst imaginable pain" (10).
The distance from the zero point gives the score, providing a simple, quick measure of symptom severity.
|
baseline, 3-day, 3-month, 6-month, 1-year, 2-year, 3-year, 5-year post-operation
|
|
Surgery time
時間枠:within 24 hours after surgery
|
The surgery duration is recorded according to the time in the surgical document, with the unit in minutes.
|
within 24 hours after surgery
|
|
Total blood loss
時間枠:within 24 hours after surgery
|
Collect the patient's height (m), weight (kg), hematocrit levels one day before and one day after surgery, and calculate the total blood loss (mL) using the Gross equation and Nadler formula.
|
within 24 hours after surgery
|
|
postoperative drainage volume
時間枠:Within 24 hours after the subject is discharged
|
The total drainage volume (mL) will be recorded by a ward nurse who is unaware of the study
|
Within 24 hours after the subject is discharged
|
|
incision length
時間枠:Within 24 hours after surgery
|
The incision length (cm) will be measured by a surgical nurse who is unaware of the study.
|
Within 24 hours after surgery
|
|
surgical costs
時間枠:Within 24 hours after the subject is discharged
|
Hospitalization costs (yuan/¥) will be calculated by a nurse who is unaware of the study, based on hospital system records.
|
Within 24 hours after the subject is discharged
|
|
intraoperative blood loss
時間枠:within 24 hours after surgery
|
Intraoperative blood loss was recorded by a nurse who was unaware of this study, including blood in the drains and in the gauze, measured in mL.
|
within 24 hours after surgery
|
|
Other lumbar spine imaging indicators
時間枠:baseline, 3-day, 3-month, 6-month, 1-year, 2-year, 3-year, 5-year post-operation
|
Measurement of dural sac cross-sectional area, lumbar spondylolisthesis rate, Cobb angle, average intervertebral disc height, and other parameters using X-ray, CT, and MRI.
|
baseline, 3-day, 3-month, 6-month, 1-year, 2-year, 3-year, 5-year post-operation
|
|
Condition of paraspinal muscles
時間枠:baseline, 3-month, 6-month, 1-year, 2-year, 3-year, 5-year post-operation
|
MRI measures paraspinal muscle area and fat infiltration rate by analyzing cross-sectional images from the lumbar spine.
|
baseline, 3-month, 6-month, 1-year, 2-year, 3-year, 5-year post-operation
|
|
Muscle injury
時間枠:1 day before surgery, 1 day and 3 days after surgery
|
CK (creatine kinase) and CK-MB are blood biomarkers used to assess muscle damage after lumbar fusion surgery
|
1 day before surgery, 1 day and 3 days after surgery
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- LUSETLIFvsMISTLIF
- MR-44-26-026507 (その他の識別子:National Clinical Research Center of China)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
- ICF
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。